Abstract Exposure to air pollution negatively impacts cardiovascular health. Studies show that increased exposure to a number of airborne pollutants increases the risk for cardiovascular disease progression, myocardial events, and cardiovascular mortality. A hypothesized mechanism linking air pollution and cardiovascular disease is the development of systemic inflammation and endothelium dysfunction, the latter of which can result from an imbalance of vasoactive factors within the vasculature. Endothelin-1 (ET-1) is a potent peptide vasoconstrictor that plays a significant role in regulating vascular homeostasis. It has been reported that the production and function of ET-1 and its receptors are upregulated in a number of disease states associated with endothelium dysfunction including hypertension and atherosclerosis. This mini-review surveys epidemiological and experimental air pollution studies focused on ET-1 dysregulation as a plausible mechanism underlying the development of cardiovascular disease. Although alterations in ET-1 system components are observed in some studies, there remains a need for future research to clarify whether these specific changes are compensatory or causally related to vascular injury and dysfunction. Moreover, further research may test the efficacy of selective ET-1 pharmacological interventions (e.g., ET A receptor inhibitors) to determine whether these treatments could impede the deleterious impact of air pollution exposure on cardiovascular health.
Introduction
Air pollution is a complex mixture of gases, particulates, and other molecules that permeate the atmosphere, making exposure largely unavoidable in most indoor and outdoor settings. Outdoor, or ambient, pollution can be produced by exhaust from numerous sources, including motor vehicles, coal-fired power plants, industrial processes, agricultural dust, and smoke from biomass, structural, and wild fires. Incomplete fuel combustion from open fires (wood, coal, organic matter) and cooking stoves is the major source of indoor or household air pollution [1] . Sources of particulate matter (PM), such as cigarette smoke, can affect individuals in both indoor and outdoor locations. All sources of PM have the potential to impact human health, but while household pollution impacts individuals on a personal level, ambient pollution has the potential to influence global health. To address this issue, several countries have passed air quality laws designed to reduce air pollution through the regulation of a variety of specific air toxics. For example, in the USA, 187 air toxics, including acrolein, lead, and ozone, are regulated by the Clean Air Act passed in 1963 [2] . Numerous other policies have been introduced to decrease annual pollution levels, and new technologies have been introduced that work to remove contaminants from smoke and other aerosols before these reach the atmosphere [3] . These efforts led to a 49 % decrease in aggregate emissions between 1980 and 2006 [4] and to an average 72 % drop in emissions of the six most common pollutants: particles, ozone, lead, carbon monoxide, nitrogen dioxide, and sulfur dioxide [2] . Despite the concerted efforts, decreases in PM are not sufficiently effective enough to prevent pollution-induced impacts on human health. The World Health Organization (WHO) attributed 7 million premature fatalities in 2012 to exposure from ambient and indoor air pollution, which roughly equates to 1 in 8 global deaths [4] . WHO attributed the majority of these deaths to cardiovascular diseases (CVD), with 37 and 33 % due to stroke and ischemic heart disease, respectively. Minor causes of death included respiratory conditions (24 %) and lung cancer (6 %) [5] . In the USA, the Centers for Disease Control and Prevention attributes an annual 600,000 American deaths to heart disease, emphasizing the significant burden of heart disease on a national level [6] . Although air pollution has a low odds ratio for the increased risk of myocardial infarction (MI) (1.02; CI 1.01-1.02), the 100 % exposure rate significantly increases the percentage of MIs attributable to air pollution, with levels similar to physical exertion and alcohol [7] . Although epidemiological studies well support an association between air pollution and CVD, this research is insufficient to elucidate the mechanisms responsible, and thus, more research is required in order to ultimately improve pollution-related health outcomes. Based on the health and financial burden of CVD, it is necessary from medical, legislative, and economic standpoints to continue working toward decreased air pollution emissions in an effort to collectively reduce morbidity and mortality and to reveal the biological mechanism(s) by which air pollution causes and/or exacerbates CVD.
Air Pollution and Cardiovascular Disease
Over the past 20 years, a number of clinical and epidemiological studies have established the damaging effects of air pollution on human health. The majority of this damage is found in the pulmonary and cardiovascular systems, leading to an increased risk of heart disease or stroke. Many of these health effects are linked to different forms of air pollution, including ambient air pollution and diesel and gasoline engine exhausts (GEEs). Ambient air pollution is composed of a gaseous suspension of aerosolized particles that typically have an aerodynamic diameter \10 lm [8, 9] ; this range is classified into specific particle sizes: ultrafine (\0.1 lm), fine (PM 2.5 , 0.1-2.5 lm), and coarse (PM 10 , [2.5-10 lm). There is strong evidence linking increased levels of PM 2.5 with increased cardiovascular effects [8, 10, 11] . A 10 lg/m 3 increase in PM 2.5 levels is associated with an increased risk of heart failure hospitalization [12] and with long-term all-cause mortality [13] [14] [15] [16] [17] .
Additional studies of specific types of air pollutants further strengthen the link between exposure and cardiovascular events. PM 2.5 exposure significantly increases left ventricular mass [18] and systolic [19] [20] [21] and mean ambulatory arterial [22] blood pressures. Changes in PM 2.5 are associated with the onset of MIs [23] and increased intima media thickness progression [24, 25] , with accelerated carotid intima media thickness (CIMT) progression of up to 5.5 lm (per 10 lg/m
3 ) per year [26] . Similarly, exposure to diesel exhaust (DE) and traffic-related pollution increases arterial stiffness [27] and systolic blood pressure [28] and is associated with both increased mortality hazard ratio and increased risk of dying after hospital discharge [29] . Collectively, these pathogenic changes (e.g., increased CIMT, increased blood pressure) suggest that an underlying vascular alteration or dysfunction is responsible, and thus, there is a need to explore mechanisms consistent with these vascular manifestations.
Brook et al. [11] propose three likely mechanisms by which air pollution may contribute to the development of CVD: (1) an imbalance in the autonomic nervous system; (2) translocation of particles, specifically ultrafine PM, into the circulation; and (3) the development of systemic oxidative stress and inflammation within the vasculature. These hypothetical pathways are generally accepted [10, 22, 27, [30] [31] [32] [33] [34] [35] . A primary outcome of these mechanisms is the initiation of endothelium dysfunction, which appears central (perhaps as a result of or in combination with oxidative stress and inflammation) to further development of CVD. Evidence suggests a strong association between endothelium dysfunction and cardiovascular events, leading to high morbidity and mortality from CVD [36] as well as other disease states [37] [38] [39] [40] [41] [42] . Endothelium dysfunction is characterized by an imbalance between the dilator and constrictor forces in the vasculature. For example, this is best exemplified by concurrent decreased formation and bioactivity of nitric oxide (NO, derived from endothelial nitric oxide synthase, eNOS) and increased levels or activity of the endothelium-derived vasoconstrictor peptide endothelin-1 (ET-1) [36] . Thus, the latter is the focus of this mini-review.
The Endothelin System
Endothelin-1 (ET-1)
Research in the early 1980s led to the chemical identification of the endothelium-derived relaxant factor NO that is recognized as one of the most important factors in regulating vascular smooth muscle tone [43, 44] . Soon after, it became obvious that the endothelium also produces a vasoconstrictor to counteract NO's effect and maintain vascular homeostasis. Yanagisawa et al. [45] isolated and sequenced the gene for a vasoconstrictive endothelin peptide; two more isoforms were later discovered, and the peptide sequenced by Yanagisawa was termed ET-1, with the subsequent peptides named endothelin-2 (ET-2) and endothelin-3 (ET-3) [46] [47] [48] [49] [50] [51] . A fourth isoform has since been discovered, but evidence suggests that this peptide serves solely as an intestinal smooth muscle constrictor [49, 52, 53] . Of these four, ET-1 is the predominant isoform, and it exerts the greatest vasoconstrictive effect [49, 51, 54] . ET-1 is a 21-amino acid peptide formed by the cleavage of pro-ET-1 (aka big ET-1) by the endothelial cell-specific endothelin-converting enzyme, ECE-1, into the active form [45, 49, 51, 54, 55] (Fig. 1) . As expected, the endothelium is the most common source of ET-1 production, but the peptide may also be produced by vascular smooth muscle cells, cardiomyocytes, macrophages, leukocytes, and fibroblasts [47, 54, 56] . A number of physical and chemical factors upregulate the expression of the ET-1 gene: reactive oxygen species (ROS) [57] , angiotensin II [48, 54, [56] [57] [58] , cytokines [56, 58] , tumor necrosis factor-alpha (TNFa) [54, 57] , interleukins [54, 57] , insulin [48, 54] , norepinephrine [54] , transforming growth factor-beta (TGFb) [48, 54, [57] [58] [59] , thrombin [48, 54, 56, 57, 60] , and exposure to cold temperature [61] . Despite the number of factors that have the potential to increase ET-1 production, the physiological range of plasma ET-1 levels in a healthy individual is both relatively low (pg/ml) and narrow, emphasizing the tight homeostatic regulation of this potent peptide [47, 57, 58, 62] .
ET-1 Receptors
Once secreted, ET-1 binds to one of its two G-proteincoupled receptor types to mediate its downstream effects [56, 63, 64] . The ET A receptor, found on vascular smooth muscle cells and cardiomyocytes, mediates a contractile response, while the ET B receptor, found on vascular endothelial, epithelial, endocrine, and nerve cells, generally causes the release of vasodilators and is also responsible for the rapid clearance of ET-1 from the vasculature [56, [63] [64] [65] [66] . Binding to the ET B receptor also stimulates the Akt pathway, leading to phosphorylation of eNOS and production of NO [56, 63] . As expected, these receptors are distributed in high levels throughout the vasculature, and although the ET A receptor is found in higher levels in the heart, the ET B receptor has a greater distribution in the lungs and kidneys [54, 62, 67, 68] . A subtype of the ET B receptor, ET B2 , also causes vasoconstriction, but it is not found widely throughout the vasculature, and its activity is negligible in healthy individuals [54, 58, 69] . Upon binding to the ET A receptor, ET-1 produces a vasoconstrictive response that is 100-times more potent than norepinephrine, thus making it the most potent vasoconstrictor known [51, 70] . ET-1-mediated vasoconstriction decreases forearm blood flow and causes a significant increase in blood pressure [71] [72] [73] [74] [75] ; prolonged ET-1-induced constriction facilitates the development of hypertension [20, 76, 77] and promotes atherosclerosis [47, 48, 51, 54, [78] [79] [80] . ET-1, however, under normal conditions, maintains vascular tone [64, 81] in balance with NO. Moreover, ET-1 is necessary for proper skeletal development of the head and neck [82] [83] [84] and the formation of the vasculature in and around the heart [85] , as well as control of embryonic heart rate [86] .
Physiology and Pathology of the Endothelin System
Like all homeostatic mechanisms in the body, the interaction between ET-1 and NO must be in balance in order for the vascular system to function properly, and it is when these two factors become unbalanced that pathological states such as endothelium dysfunction can begin to develop. Although endothelium dysfunction is commonly assessed as a decrease in NO production, it can be caused by an increase in ET-1 production [49, 51, 78] . Nonetheless, it is important to consider that increased ET-1 activity could also be caused by decreased ET-1 clearance and/or by lower levels of NO production or stability [78] . Decreased NO in the vasculature allows a greater effect of ET-1 independent of any change in ET-1 levels. Regardless of the cause, many studies, including a number of pharmacological trials, show ET-1-dependent activity initiates pleiotropic effects beyond only vasoconstriction. ET-1, working through a variety of pathways, generates ROS [87] [88] [89] such as superoxide [47, 78, 80, [88] [89] [90] ; activates macrophages, leading to increased production of pro-inflammatory mediators [64, 78-80, 89, 91-93] ; induces extracellular matrix formation [94] ; and stimulates vascular smooth muscle cell proliferation [47, 58, 80, 87, 94, 95] . Furthermore, increased ET-1 inhibits eNOS and blocks the production of NO [78, 95] . These actions can disrupt the equilibrium within the vascular wall and initiate endothelium dysfunction [11, 31, 80, 89, [96] [97] [98] [99] and, thereby, generally promote the development of CVD. Therefore, it is plausible and likely that altered ET-1 production and/or activity is one mechanism by which air pollution enhances the development of vascular dysfunction [39, 40, [75] [76] [77] [78] 99] . The endothelin system is spread along 60,000 miles of vasculature in the body, so it is within reason that dysregulation of ET-1 could have effects in multiple organ systems and potentially augment the development of other diseases. As with CVD, the vasoconstrictive effect of ET-1 is the proposed major cause of these conditions. In the extremities, cold-temperature-induced increases in ET-1 contribute to the pathogenesis of Raynaud's phenomenon [37, 100] , in which exaggerated vasoconstriction causes discomfort (ischemic pain) and discoloration of the affected areas. Likewise, ET-1-related vascular dysfunction in the eye leads to intraocular inflammation; this plays an important part in the development of primary open-angle glaucoma [41] . In the kidneys, ET-1 controls renal blood flow and the reabsorption of water and salt, as well as maintains acid-base balance [54, 57, 78, 101] . If any of these factors are disrupted, it can result in the development of hypertensive neuropathy, glomerulonephritis, or proteinuria [57, 79] . Within the pulmonary system, ET-1 is produced both by endothelial cells and by airway epithelial cells and cleared by the high levels of the ET B receptor found in the pulmonary tissue [54, 62, 67, 68] . ET-1 influences the maintenance of airway tone, and so increased production or decreased clearance may lead to bronchial constriction [54, 102] . Chronic bronchial constriction can promote asthma and chronic obstructive pulmonary disease (COPD) [38, [103] [104] [105] . ET-1 also affects the arteries and veins in the lungs, and thus, elevated ET-1 can lead to the development of pulmonary hypertension, just as it can stimulate the development of systemic hypertension [97, 106, 107] . Thus, changes in ET-1 or its activity can be a link between exposure to air pollution and the development of a variety of pathogenic states through the induction of vasoconstriction and endothelium dysfunction as prevalently seen in CVD.
Air Pollution and Endothelin-1 Human Studies
Despite the wealth of evidence described above, few studies have examined the relationship between air pollution exposure and circulating levels of ET-1 in humans, and those studies that have been performed have produced conflicting results (Tables 1, 2) . In epidemiological studies, Calderon-Garciduenas and colleagues have repeatedly examined the effects of elevated levels of air pollution on children in Mexico City, which has been shown to significantly exceed the WHO's annual mean PM 2.5 standard [108, 109] . In a 2007 study, the group measured plasma ET-1 levels in healthy children (n = 81) from both Mexico City and Polotitlán, a control city. They observed that the cumulative PM 2.5 level of the previous 7-days was associated with higher plasma ET-1 levels in the children of Mexico City [108] . Similarly, there was a positive correlation between the number of hours a child spent outdoors and plasma ET-1 levels [108] . The authors suggest that the time spent outside increased each child's exposure to air pollution that, in turn, increased plasma ET-1. In a related study, clinically healthy children (n = 28) from Mexico City and Polotitlán were used to investigate the effect of PM 2.5 on markers of systemic inflammation and endothelial cell injury. Again, Mexico City children were shown to have significantly higher levels of ET-1 and various inflammatory markers positively associated with elevated levels of PM 2.5 exposure [110] . Controlled human exposures have been performed to substantiate the findings of these few epidemiological studies and to provide a better understanding as to whether air pollution alters ET-1. A small study exposed healthy adults (n = 10) to DE (100 lg/m 3 ) and showed that DE significantly increases plasma ET-1 and matrix metalloproteinase-9 (MMP-9) compared with filtered air-exposed controls [111] . Dysregulation of MMP-9 contributes to pathological changes in the vasculature, and MMP-9 levels are increased via ET A receptor activation [111] .
Other studies, however, have found no change in the ET-1 system related to air pollution exposure or no alteration in the functional outcomes related to ET-1-induced vasoconstriction. Peretz et al. [112] exposed a mixed group of both healthy subjects and people with metabolic syndrome to 2 h of DE. They reported an average 0.11-mm greater vasoconstriction in the brachial artery in the DE exposure group regardless of health status. Likewise, plasma levels of ET-1 increased in both groups following DE exposure and to a greater degree within the healthy adults. The authors attributed this latter finding to the arterial stiffness associated with metabolic syndrome; the vessels in the diseased individuals are less responsive to the effects of DE due to decreased plasticity, whereas the vessels of the healthy individuals are capable of producing a normal vascular response and, thus, could mount a greater range of vasoconstriction. DE exposure, however, did not affect blood pressure or flow-mediated dilatation (FMD), the latter being a common indicator of endothelium function. Similarly, after a 2-h exposure to concentrated ambient air particulate matter (CAP), healthy non-smokers had no change in either FMD or in blood pressure, although they did have a significant reduction in brachial artery diameter [113] . Both Mills et al. [114] and Langrish et al. [115] exposed participants to higher levels of DE-derived PM 2.5 , which was expected to have a greater effect on the endothelium, but neither investigation demonstrated any change in the plasma levels of ET-1 or big ET-1. The varied results of these human exposure studies indicate that the effect of air pollution exposure on the ET-1 system is difficult to measure and may differ based on factors such as pollution type, the length and CAP concentrated ambient air particulate matter, DBP diastolic blood pressure, DE diesel exhaust, ET-1 endothelin-1, FMD flow-mediated dilation, FBF forearm blood flow, IL-6 interleukin-6, MMP matrix metalloproteinase, NMD endothelial-independent nitroglycerin-mediated dilatation, O 3 ozone, SBP systolic blood pressure, TNFa tumor necrosis factor-a Plasma ET-1 levels significantly higher in northeast (2.09 ± 0.10 pg/mL, p \ 0.001) and southwest (2.40 ± 0.14 pg/mL, p \ 0. Other research has focused on the targets of ET-1-the ET-1 receptors. For example, administration of the selective ET A receptor antagonist, BQ-123, is used to explore the possibility of an increased secretion of ET-1 abluminally, which would not necessarily change ET-1 levels in the plasma [48, 115] . Exposure to DE decreased the amount of vasodilation seen as a result of the BQ-123 infusion, yet previous research indicated that BQ-123-induced vasodilation was in part due to endothelial cellderived NO release mediated by the ET B receptor [116] . Thus, Langrish et al. [115] propose that DE-elicited vasoconstriction results from decreased NO bioavailability and not increased ET-1. Because NO and ET-1 must be delicately balanced in order to properly maintain the tone of the vasculature, a decrease in NO likely produces a similar effect as an increase in ET-1, so this remains a difficult relationship to disentangle. Further use of ET receptor blockers and observation of the effects of direct ET-1 administration should allow for elucidation of which of these two factors more significantly influences alterations within the vasculature.
Occupational Exposure
Occupational exposures often result in unique forms of personal air pollution exposure. A few studies have examined the cardiovascular effects of occupational traffic pollutant exposure [103, 117] . A large study of professional drivers (n = 1922) revealed that bus drivers who had more than 10 years' experience, theoretically with more engine exhaust exposure, had a twofold increased odds ratio of MI, even after adjustment for unfavorable lifestyle factors; taxi drivers also had an increased odds ratio, while there was no evidence of increased risk for truck drivers [117] . In another study, air quality monitors were used to measure personal and ambient exposure of North Carolina State Highway Patrol troopers during four successive 9-h shifts [103] . Although the report indicates lower in-vehicle PM 2.5 levels compared with ambient PM 2.5 , higher levels of other pollutants, including carbon monoxide, nitrogen dioxide, and hydrocarbons, were present in the vehicle. Furthermore, they showed that for every 10 lg/m 3 increase in PM 2.5 , the officers exhibited increased C-reactive protein (CRP), which serves as an indicator of inflammation, and increased next-morning heart rate variability (HRV). HRV, like ET-1, has been shown to be altered by increased PM 2.5 , which indicates a relationship, either direct or indirect, between these two factors [19] .
Workers in other occupations are also prone to highlevel exposures of pollution. In a study of sugarcane harvesters, higher levels of PM 2.5 are measured during the harvest season [118] . Sugarcane fields are cleared by burning, and workers are exposed to high amounts of smoke and pollutants during burning and subsequently in the harvesting of the burnt sugarcane. Both systolic and diastolic blood pressures are significantly increased in the workers during the harvest season compared with the nonharvest period [118] . Welding is another profession wherein workers are exposed to higher amounts of air pollution [119] . However, Jarvela et al. [120] determined that an 8-h dust and welding fume exposure (inhalable dust; 1.5-35 mg/m 3 ) did not significantly change the workers' levels of plasma ET-1, yet exposure to welding fumes (alveolar particle fraction; 1.0-25.3 mg/m 3 ) significantly decreased ET-1 [121] . The investigators hypothesized that this contradictory response could be due to the heterogeneous mix of the welding fumes, which included high levels of nitrogen oxides that could disrupt the homeostasis in the vasculature. Regardless, the study had insufficient evidence to accurately describe the mechanism of the response [121] , and so further research is needed to determine the cause of this somewhat paradoxical result.
Environmental and Secondhand Tobacco Smoke
When examining how air pollution contributes to the development of chronic diseases, it is important to consider not just general air pollution, but also situations where individuals may be exposed to different forms or relatively higher levels of PM 2.5 as well as other pollutants (e.g., acrolein). Cigarette smoke, for example, is strongly associated with cardiovascular and respiratory diseases, including those linked to endothelium dysfunction [122] , and again the involvement of ET-1 in the mechanistic pathway is a reasonable hypothesis. Working through the mitogen-activated protein kinase (MAPK) pathway, specifically the extracellular signal-regulated kinase (ERK) pathway, cigarette smoke upregulates the expression of mRNA for both the ET A and ET B receptors [123] , as well as ET-1 in a variety of tissues [122, 124] . These effects are readily seen in smokers, but also in individuals who are exposed to environmental or secondhand smoke (SHS), also known as passive smoking. Environmental exposure to cigarette smoke at one-hundredth the level of active smoking increases an individual's risk of coronary artery disease by 30 % [125] . Likewise, both animal and human models have shown that passive smoking is associated with increased CIMT [125] and platelet activation [125, 126] , as well as decreased vasodilatory function at levels comparable to those seen in active smokers [125] . Similarly, Cao et al. [123] demonstrate a direct effect of SHS exposure in rats on the ET-1 system as SHS activates the MAPK pathway and upregulates both ET A and ET B receptor mRNA and protein in coronary arteries. Additionally, Pinnamaneni et al. [127] show that SHS exposure as brief as 1 min causes a reversible impairment of endotheliumdependent vasodilatory function as measured by FMD in rats. Together, these studies show that the impact of SHS exposure on endothelium function and overall CVD health via dysregulation of the ET-1 system is just as relevant as exposure from active smoking and may in fact have a greater disproportional impact on CVD due to the unintentional exposure of the general public.
Animal Studies
Both environmental and controlled exposures in animals show a consistent trend between air pollution and alterations in ET-1 levels (Tables 3, 4 ). Mice exposed to GEE or DE have significant increases in plasma ET-1 [128] , ET-1 mRNA expression in the aorta [104, 128] , and ET-1-induced vasoconstriction [129] . Some studies also noted elevated plasma levels of MMPs [104, 111, 128] , which, as noted, are upregulated via activation of the ET A receptor [111] . Similarly, air pollution exposures in rats induced effects consistent with those observed in exposed mice. For example, exposure of rats to DE enhances both the arterial vasoconstriction response to ET-1 [130] and the expression of ET-1 and ET A receptor mRNAs [131] . A combination exposure of DE particles and ozone also increases the expression of the ET B receptor in the aorta [131] . Similarly, CAP exposure in rats upregulates the mRNA expression of the ET A receptor in the heart [132] , and inhalation of urban dust particles increases plasma ET-1 levels and decreases the production of pulmonary NO [133] . In rabbits, PM 10 exposure significantly increases plasma ET-1 levels [134] . Thus, in a number of different animal models, well-designed exposure experiments provide evidence that a variety of air pollutants (e.g., PM, PM ? O 3 , DE, GEE) are capable of increasing the level of plasma ET-1 and/or enhancing its receptors in the vasculature while decreasing NO status. These changes likely prime blood vessels for endothelium and vascular dysfunction.
ET-1, Air Pollution, and Diabetes: Is There a Connection?
A 2013 study stated that there are an estimated 381.8 million people with diabetes; that number is expected to climb another 55 % by 2035 [135] . Although this estimate includes both type 1 and type 2 diabetes, the more important form of the disease in regard to ET-1 is type 2 (T2D). T2D is caused by cellular insulin resistance (IR) [136, 137] , which in turn causes high levels of glucose to remain in the circulation, leading to hyperglycemia. A number of studies have shown that endothelium dysfunction often occurs in conjunction with IR; because dysregulated levels of ET-1 are known to contribute to endothelium dysfunction, many have suggested that ET-1 can thus cause IR [80, [136] [137] [138] [139] [140] . A study of genetically obese rats supports this hypothesis: basal plasma ET-1 levels are increased in the first 7 weeks during the progression of IR [138] . Alternatively, insulin itself can stimulate the production of ET-1 [54, 136, 137] via ERK signaling [80] , which can then act to reduce the insulin sensitivity of target tissues and exacerbate IR [137] . Yet other studies find no significant increase in plasma ET-1 levels in diabetic or IR individuals [141, 142] . At least one of these studies, however, measured ET-1 in venous samples 2 h after inducing physiological hyperinsulinemia [141] . The authors concede that they could not rule out a transient increase in ET-1, and because the half-life of ET-1 is only approximately 1 min [47, 65, 66] , it is possible that the blood collection protocol used was unlikely to detect rapid changes in plasma ET-1. Furthermore and importantly, both Dhaun et al. [57] and Langrish et al. [115] point out that most of the ET-1 is released abluminally with only small amounts making it into the plasma, and so plasma concentrations of ET-1 may not accurately reflect physiological alterations within the vascular wall. Also, there is an inability to measure endothelial cell ET-1 in vivo to verify whether or not more ET-1 is being made in the endothelium. Collectively, these factors could account for the general lack of significant findings that link plasma ET-1 levels with cardiovascular outcomes [113] .
Recently, research has begun to look into possible associations between air and water pollution and chronic diseases such as T2D. Reviews of studies relating air pollution and T2D show support for an association between the two factors [143, 144] , particularly air pollution from traffic exposure and human T2D [144] . Exposures to PM 2.5 are associated with elevated fasting blood glucose and insulin in mice, leading to the development or exaggeration of whole-body IR [145, 146] , and PM 10 exposure has been associated with elevated glycated hemoglobin (HbA 1c ) levels in newly diagnosed diabetics [147] . These studies have shown that exposure to air pollution downregulates insulin receptor substrate 1 signaling and inhibits the Akt pathway, resulting in decreased Akt signaling while leaving the ERK pathway unaffected [144, 146] . Based on this evidence, it is logical to propose that, as with CVD, air pollution can lead to the development of T2D in part via increased signaling of the ERK pathway, leading to increased production of ET-1 and endothelium dysfunction. Thus, aside from CVD, diabetes mellitus would likely be the most prevalent condition resulting from dysregulation of the ET-1 system.
Endothelial Progenitor Cells (EPCs) and ET-1
It would furthermore be beneficial to examine the relationship between ET-1 and endothelial progenitor cells (EPCs). EPCs are stem cells produced by the bone marrow in response to vascular injury. Once activated, these cells differentiate into new endothelial cells to replace damaged cells in the vasculature [148] . Exposure to PM 2.5 has been shown to deplete circulating levels of EPCs in humans [149] and mice [150] , the latter study indicating a mechanism related to VEGF resistance; both studies suggest lower EPCs reduce vascular repair. Similar EPC and VEGF resistance effects were found in mice exposed acutely to acrolein [151] , although ET-1 was not measured. Studies with tyrosine kinase inhibitors have shown that inhibition of the VEGF receptor stimulates the ERK pathway, increasing the expression of prepro-ET-1 while also inhibiting the Akt pathway and decreasing NO production [152] [153] [154] [155] . These results strengthen the hypothesis that VEGF resistance is a key component in the mechanism through which air pollution influences ET-1 and, downstream, EPCs. A small number of studies have looked at ET-1 and EPCs in relation to ischemic stroke [148] , diabetes [156] , and cancer [157] , but none of these studies have been specifically designed to relate ET-1 and EPCs with air pollution. A study with this focus could shed light on a new role of ET-1, if any, in the release of EPCs from the bone marrow and how the two factors also may interact within the vasculature.
Concluding Remarks
Our understanding of the role of air pollution in the development of CVD has been furthered by examining the role of ET-1 in the vasculature. Epidemiological observations and controlled exposures in both humans and animals show an association between air pollution exposure and cardiovascular effects; many have identified dysregulation of ET-1 as a possible mechanism underlying this association, likely via inhibition of the Akt pathway and increased stimulation of the ERK pathway, thus leading to greater ET-1 production and decreased production of NO. There seems to be a more consistent relationship in animal studies, however, compared with human studies, although this is likely more reflective of our ability to control all aspects of the exposure and a more complete set of measurements made in animal studies. Additional human studies specifically designed to measure ET-1 levels in relation to functional vascular parameters (e.g., blood CO carbon monoxide, DE diesel exhaust, ET-1 endothelin-1, GEE gasoline engine exhaust, HO-1 heme oxygenase 1, MMP matrix metalloproteinase, NO nitric oxide, PM particulate matter, ROS reactive oxygen species, TIMP-2 TIMP metallopeptidase inhibitor 2 pressure, forearm blood flow, and brachial artery diameter) are needed to improve our understanding of the peptide's role in homeostatic maintenance after exposure to pollution. As ET-1 is more likely a paracrine signaling molecule, measuring local ET-1 levels would more accurately reflect the levels produced in response to exposures. For example, more invasive and direct evaluations of released ET-1 by using endothelial cell biopsy or abluminal wick measurements would allow for assessment of ET-1 levels in specific vascular locations. Additional studies are also needed to determine what role pollution exposure plays in the levels of ET-1 in healthy versus diseased individuals. It is known that older or obese individuals or those with preexisting heart or respiratory conditions are more susceptible to the effects of air pollution [11] ; it is therefore necessary to study the effects of air pollution in a number of different population groups. It would also be beneficial to examine ET-1 levels in more individuals with higher levels of occupational exposure. Firefighters in particular have high incidence of CVD and are exposed to high levels of pollutants on a frequent yet irregular basis, making them an ideal population in which to study the relationship between exposure and ET-1 [158] . Only one study has currently examined ET-1 levels in a population of firefighters, examining firefighters who participated in a computerized fire strategies and tactics drill, a program meant to simulate the physical and mental response to fighting an actual fire. This study showed no difference in plasma ET-1 compared with an exercise only group [159] . Levels did show a significant rise in the simulation group during a recovery period, which may indicate increased levels of ET-1 in response to mental stress. However, since neither group was exposed to true air pollution, and especially not at the levels to which they would be subjected during a response to an actual fire, it is unclear what acute exposure to high levels of smoke may have on ET-1 levels. Furthermore, the study reports levels of ET-1 in ng/mL, which is three orders of magnitude higher than what is reported in other studies of ET-1 and air pollution exposure, making a true comparison difficult. Thus, more studies are needed to gain a clearer understanding of this relationship in individuals who are occupationally exposed to high levels of air pollution.
Further research could make more effective use of endothelin receptor blockers. A number of ET receptor blockers have been developed and tested [49, 76, 98, 106, 160, 161] , but only a small number have been approved for medical use. Bosentan, one of the approved drugs, is a dual endothelin receptor (ET A , ET B ) antagonist approved for the treatment of pulmonary arterial hypertension that has proven to be quite effective in blocking the effects of ET-1 in the lung vasculature [107, [162] [163] [164] . The development and approval of other endothelin receptor blockers may help reduce the number of new cases of hypertension, atherosclerosis, and IR by decreasing the influence of ET-1 in the vasculature and maintaining the balance between ET-1 and NO. Balancing these two factors pharmacologically could help improve overall cardiovascular health in spite of general or specific pollution exposures. Nonetheless, thorough investigation using explicitly designed experimental exposures and collection protocols should better define ET-1's role as a link between air pollution exposure and CVD. This information could then be used to combat the detrimental impact of air pollution on the cardiovascular health of the human public.
